Effektresultater ved Uge 48 (Studie 138) for CVR (NC=F) analysen
Efficacy Outcomes at Week 48 (Study 138) for the CVR (NC=F) analysis REYATAZ/ ritonavira lopinavir/ ritonavirb (300 mg/ 100 mg (400 mg/ 100 mg once daily) twice daily)